Author:
Hanthamrongwit Jariya,Aruvornlop Panicha,Saelee Chutiphon,Wanta Nattiya,Poneksawat Passarun,Soe Phyu Thwe,Kyaw Soe Paing,Khaenam Prasong,Warit Saradee,Valentini Davide,Mahasirimongkol Surakameth,Dhepakson Panadda,Soonthornchartrawat Sakulrat,Chootong Patchanee,Leepiyasakulchai Chaniya
Abstract
AbstractMulti-stage tuberculosis (TB) vaccines composed of active- and dormancy-associated antigens are promising to trigger the immune protection against all TB stages. However, scientists are still in quest of the suitable vaccine candidates. In this study, we identified the potential targets for this vaccine in a high TB burden country, Thailand. Peptide microarray was applied to gauge IgA and IgG antibodies specific to 16,730 linear epitopes of 52 dormancy-associated Mycobacterium tuberculosis (M. tb) proteins in three study groups: active tuberculosis (ATB), latent tuberculosis infection (LTBI) and endemic healthy control (EHC). Preferential IgA recognition against epitopes of dormancy-associated proteins was identified in LTBI group. Validation of these findings revealed that LTBI subjects exhibited the greater levels of Rv2659c- and Rv1738-specific IgA than those of household contacts, but less than did ATB subjects. Frequencies of IFNγ-producing CD4+ and CD8+ T cells induced by proteins Rv2659c and Rv1738 were higher in LTBI than ATB individuals. The results indicated that LTBI group in a high TB burden country demonstrated cell-mediated immune response to proteins Rv2659c and Rv1738 stronger than those of ATB. These immune responses likely contribute to natural protection against dormant M. tb and might be potential targets for a multi-stage TB vaccine.
Funder
Thailand Graduate Institute of Science and Technology, National Science and Technology Development Agency
National Vaccine Institute of Thailand
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. World Health Organization. Global Tuberculosis Report 2021 (World Health Organization, 2021).
2. Sharma, S. K., Mohanan, S. & Sharma, A. Relevance of latent TB infection in areas of high TB prevalence. Chest 142, 761–773. https://doi.org/10.1378/chest.12-0142 (2012).
3. Kaufmann, S. H. E., Weiner, J. R. & Maertzdorf, J. Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers. Expert. Rev. Vaccines 16, 845–853. https://doi.org/10.1080/14760584.2017.1341316 (2017).
4. World Health Organization. Implementing the End TB Strategy: The Essentials (World Health Organization, 2015).
5. Cho, T. et al. A review of the BCG vaccine and other approaches toward tuberculosis eradication. Hum. Vaccin. Immunother. 17, 2454–2470. https://doi.org/10.1080/21645515.2021.1885280 (2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献